Why the study?
Although not all Purkinje-myocardial junctions are active at rest due to source-sink mismatch, whether gap junction uncoupling during acute ischaemia increases active junctions and activation complexity was unclear.
Comparison
Rotigaptide vs control during an ischaemia-reperfusion protocol
Design
Ex vivo optical mapping and computational modelling study
Key result
Acute ischaemia increased the number of active Purkinje-myocardial junctions, causing a paradoxical acceleration in right ventricular activation that was abolished by the gap junction enhancer rotigaptide.
Authors
Loading...
Suggests gap junction modulation may alter ischaemic conduction in animals; leaves open clinical relevance for human ventricular arrhythmias.
Absolute Event Rate: 52% vs 62%
p-value: p=0.04
Acute ischaemia increases the number of active Purkinje-myocardial junctions leading to complex activation patterns, which can be mitigated by the gap junction enhancer rotigaptide.
Jabbour et al. (2025) studied Acute ischaemia (n=12). Rotigaptide vs. Control (no rotigaptide) was evaluated on Percentage of right ventricle area activated within the first 5 ms (early ischaemia vs baseline) (p=0.04). Acute ischaemia increased the number of active Purkinje-myocardial junctions, causing a paradoxical acceleration in right ventricular activation that was abolished by the gap junction enhancer rotigaptide.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: